Article Per Year (5 Year)
p-Index From 2021 - 2026
1.203
P-Index
This Author published in this journals
All Journal Medical Journal of Indonesia Universa Medicina Indonesian Journal of Cardiology Narra J Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Bambang Widyantoro
Department Of Cardiology And Vascular Medicine, Faculty Of Medicine, Universitas Indonesia- National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 13 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 13 Documents
Search

 1   2 
Divergent roles of circulating miR-133 and miR-155 in modulating angiotensin II levels among hypertensive patients in Melanesian and non-Melanesian populations Wijaya, Shoma A.; Pujianto, Dwi A.; Prijanti, Ani R.; Widyantoro, Bambang
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.1759

Abstract

The therapeutic approach to hypertension often varies across racial and ethnic groups; however, antihypertensive treatments have not yet been tailored to account for these variations in Indonesia, a country with diverse racial and ethnic groups. In addition, microRNA-133 (miR-133) and microRNA-155 (miR-155) play critical roles in cardiac muscle homeostasis and inflammatory responses, but their specific functions in hypertension remain unclear. The aim of this study was to investigate the correlation between circulating miR-133 and miR-155 levels and angiotensin II (ANG-II) levels in hypertensive patients from Melanesian and non-Melanesian populations in Indonesia. A cross-sectional study was conducted in Jayapura, Indonesia among Melanesian and non-Melanesian hypertensive patients. The levels of ANG-II were quantified using sandwich ELISA, while the relative expression of miR-133 and miR-155 levels were measured by real-time PCR. Differences between the two groups were assessed using the Mann-Whitney test, and correlations between miR and ANG-II levels were determined using the Spearman correlation test. The relative expression levels of miR-133 and miR-155 in the Melanesian group were significantly higher than in the non-Melanesian group; 6.94-fold (3.85 vs 0.55) and 2.1-fold higher (0.19 vs 0.09), respectively. MiR-133 had a moderate negative correlation with ANG-II in both Melanesian (r=-0.538; p<0.001) and non-Melanesian (r=-0.649; p<0.001). However, miR-155 had no significant correlation with ANG-II levels in either the Melanesian group (p=0.551) or non-Melanesian group (p=0.159). This study highlights that miR-133 levels are significantly correlated with ANG-II concentrations in both Melanesian and non-Melanesian hypertensive patients, suggesting that miR-133 may play a regulatory role in the ANG-II pathway. These findings provide insights into the potential of miR-133 as a biomarker for hypertension management in diverse populations.
Latihan Fisik bagi Penderita Hipertensi Arum Widi Sarastuti; Bambang Widyantoro
Cermin Dunia Kedokteran Vol 45 No 12 (2018): Interna
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v45i12.687

Abstract

Hipertensi merupakan faktor risiko utama penyakit kardiovaskular, yang jika tidak diterapi secara tepat dapat meningkatkan morbiditas dan mortalitas. Latihan fisik merupakan salah satu bentuk upaya nonfarmakologis pencegahan, pengobatan, serta rehabilitasi pasien hipertensi. Dosis latihan fisik hendaknya sesuai kondisi masing-masing penderita hipertensi. Hypertension is a major risk factor for cardiovascular disease which, if not properly treated, can increase morbidity and mortality. Exercise is non-pharmacological method in prevention, treatment, and rehabilitation of hypertension. The dose of physical exercise should be appropriate.
Management of Decongestion in Acute Heart Failure: Time for a New Approach? Pramudyo, Miftah; Putra, Iwan Cahyo Santosa; Zulkarnain, Edrian; Danny, Siska Suridanda; Bagaswoto, Hendry Purnasidha; Anjarwani, Setyasih; Mazwar, Irmaliyas; Juzar, Dafsah Arifa; Pratama, Vireza; Habib, Faisal; Ispar, Akhtar Fajar Muzakkir Ali; Widyantoro, Bambang
Jurnal Kardiologi Indonesia Vol 43 No 2 (2022): Indonesian Journal of Cardiology: April - June 2022
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.1381

Abstract

As the primary cause of hospitalization in acute heart failure (AHF) patients, congestion was responsible for a higher risk of mortality, rehospitalization, and renal dysfunction in AHF patients. Although loop diuretic was routinely used as the mainstay of AHF therapy, it is still ineffective to obtain the euvolemic state in most hospitalized AHF patients. Therefore, a higher loop diuretic dose was often required to increase the decongestion effect. However, consequently, it can cause several detrimental complications, including renal dysfunction, neurohormonal activation, hyponatremia, hypokalaemia, and reduced blood pressure, which eventually result in poor prognosis. Hence, the new approach may be proposed to optimize decongestion in acute phase, including the use of arginine vasopressin V2 receptor antagonist – Tolvaptan. As an additive therapy to loop diuretic in AHF patients, it can be considered due to its several beneficial effects, including greater decongestion effect, lowered worsening renal function incidence, counteract neurohormonal activation, neutralized hyponatraemic state, no alteration of potassium metabolism, stabilize the blood pressure, and reduced requirement of a higher dose of loop diuretic to achieve an equal or even greater decongestion effect compared to a high dose of loop diuretic alone. Tolvaptan provided favourable outcomes in several specific populations and was considered safe with several mild adverse effects. Several guidelines across countries have approved the use of Tolvaptan in AHF patients with or without hyponatremia. The initial dose of Tolvaptan was 7.5 to 15 mg and can be titrated up to 30 mg. However, further studies were still required to determine the timing dose and optimal dose of Tolvaptan in general and elderly populations with AHF, respectively.
Co-Authors Akhtar Fajar Muzakkir Andi Alfian Zainuddin Andria Priyana Ani R. Prijanti Anjarwani, Setyasih Anwar Santoso Arieska Ann Soenarta Arum Widi Sarastuti Arum Widi Sarastuti Astiawati, Tri Daniel PL Tobing Dian Zamroni Dwi A. Pujianto Dwi Putra, Swastya Dwi Yuda Herdanto Dwiputra, Bambang Ebtehal Salman Eka Harmeiwaty Endang, Jusup Habib, Faisal Hakim, Afdhalun Hendry Purnasidha Bagaswoto Hilman Zulkifli Amin, Hilman Zulkifli Ilhami, Yose Ramda Irmalita Irmalita Isman Firdaus Ispar, Akhtar Fajar Muzakkir Ali Juzar, Dafsah Arifa Mazwar, Irmaliyas Muliawan, Hary Sakti Muzakkir, Akhtar Fajar Nahar Taufiq, Nahar Noriko Matsushita Pramudyo, Miftah Pratama, Vireza Putra, Iwan Cahyo Santosa R A, I Made Junior Rarsari Soerarso Renan Sukmawan Rezeki, Arindya Rossimarina, Vienna Sarastuti, Arum Widi Siska Suridanda Danny Siska Suridanda Danny Tunggul Diapari Situmorang Vidya Gani Wijaya Wijaya, Shoma A. Yuda Turana Zulkarnain, Edrian